3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Dermatologic
2
Thoracic
1
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Interventions
Prednisone
122
Docetaxel
118
enzalutamide
101
pembrolizumab
96
Sunitinib
86
Leuprolide
84
Abiraterone Acetate
83
Nivolumab
78
Gemcitabine
76
bicalutamide
54
Radiotherapy
54
Goserelin
54
Bevacizumab
54
Cisplatin
52
Magnetic Resonance Spectroscopy
49
Everolimus
49
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
46
Sorafenib
40
Carboplatin
40
Paclitaxel
37
Radiosurgery
36
atezolizumab
35
abiraterone
33
pazopanib
32
cabozantinib
32
Ipilimumab
32
Axitinib
30
Cyclophosphamide
29
Androgen Antagonists
29
Radiation
28
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
linrodostat
×
Genitourinary
×
Clear all
NCT03519256
2023-06-01
CheckMate 9UT
Bristol-Myers Squibb
Phase 2
Terminated
142 enrolled
20 charts